Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharma (CRNX)
:CRNX
CRNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.10 - $62.53
Previous CloseN/A
Volume214.21K
Average Volume (3M)1.10M
Market Cap
$3.11B
Enterprise Value$3.38B
Total Cash (Recent Filing)-$12.15M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.55
Next Earnings
May 08, 2025EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.70
Shares Outstanding93,048,540
10 Day Avg. Volume970,964
30 Day Avg. Volume1,102,843
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3082.51
Price to Cash Flow (P/CF)-12.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.25K
Enterprise Value/Ebitda-10.04
Forecast
1Y Price Target
$78.20Price Target Upside134.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
---
Crinetics Pharmaceuticals News
See All CRNX News
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company is well-capitalized with a strong balance sheet, holding $1.4 billion in cash and equivalents, which provides financial stability and the ability to invest in growth opportunities.
Market ExpansionCrinetics Pharmaceuticals has established a hub in Switzerland and added EU launch leadership, indicating strong strategic planning for global expansion.
Product LaunchThe impending approval of Paltusotine in Acromegaly by its PDUFA date indicates a near-term catalyst for the company, supporting the current stock valuation.
Bears Say
Clinical DataCRNX shares have been trading down following safety concerns from the Phase 2 atumelnant data in congenital adrenal hyperplasia (CAH) reported in January 2025.
Investor SentimentSome investors were disappointed that the data from the Phase 2 TouCAHn study wasn't quite as robust as initially reported.
Safety ConcernsThere are lingering questions around transient liver signals in the Atumelnant program, adding uncertainty to its safety profile and overshadowing its otherwise promising data.
---
Ownership Overview
2.09% Insiders
38.91% Mutual Funds
0.09% Other Institutional Investors
42.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRNX FAQ
What was Crinetics Pharma’s price range in the past 12 months?
Crinetics Pharma lowest stock price was $24.10 and its highest was $62.53 in the past 12 months.
What is Crinetics Pharma’s market cap?
Crinetics Pharma’s market cap is $3.11B.
When is Crinetics Pharma’s upcoming earnings report date?
Crinetics Pharma’s upcoming earnings report date is May 08, 2025 which is in 12 days.
How were Crinetics Pharma’s earnings last quarter?
Crinetics Pharma released its earnings results on Feb 27, 2025. The company reported -$0.88 earnings per share for the quarter, beating the consensus estimate of -$0.886 by $0.006.
Is Crinetics Pharma overvalued?
According to Wall Street analysts Crinetics Pharma’s price is currently Undervalued.
Does Crinetics Pharma pay dividends?
Crinetics Pharma does not currently pay dividends.
What is Crinetics Pharma’s EPS estimate?
Crinetics Pharma’s EPS estimate is -0.94.
How many shares outstanding does Crinetics Pharma have?
Crinetics Pharma has 93,048,540 shares outstanding.
What happened to Crinetics Pharma’s price movement after its last earnings report?
Crinetics Pharma reported an EPS of -$0.88 in its last earnings report, beating expectations of -$0.886. Following the earnings report the stock price went up 7.739%.
Which hedge fund is a major shareholder of Crinetics Pharma?
Currently, no hedge funds are holding shares in CRNX
---
Crinetics Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$78.20 (134.20% Upside)
$78.20 (134.20% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 14.6%
Last 30 Days ▲ 14.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.92%
12-Months-Change
Fundamentals
Return on Equity
-32.02%
Trailing 12-Months
Asset Growth
171.68%
Trailing 12-Months
Company Description
Crinetics Pharma
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
---
CRNX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in regulatory milestones, clinical trial advancements, and financial stability. However, it also noted challenges such as revenue decline, increased net loss, and high anticipated cash burn. Overall, the positive developments in drug approvals and clinical trials suggest optimism for future growth.Read More>---
CRNX Stock 12 Month Forecast
Average Price Target
$78.20
▲(134.20% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Viking Therapeutics
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Immunovant
―
Best Analysts Covering CRNX
1 Year
1 Year Success Rate
11/19 ratings generated profit
1 Year Average Return
+35.75%
reiterated a buy rating 2 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +35.75% per trade.
---